Dr. David Shlaes

Musings on the Future of Antibiotic Biotech

Abbvie is buying Allergan – but not for its antibiotic franchise. They are more interested in Botox and other esthetic produ

Antibiotic Awareness Week - Talk vs. Action?

This is antibiotic awareness week. To mark this week, there has been a great deal of talk and the publication of several important papers and workshops on antibiotics and resistance.

The $2 Billion Bomb: Rewards for New Antibiotics

When legislators and policymakers try to do just about anything to encourage innovation—especially in drug research—it rarely works. This is because, for the most part, they have absolutely no idea what it takes to discover a drug. None.

Antibiotics: Some Welcome Movement at the FDA

Top antibiotic Doc weighs in on solutions to resistance problem

Back

Antibiotics hit the news big time. But is it in time?

We at ACSH have been writing about the dire situation we face because

The FDA may be doing something productive to combat antibiotic resistance

The federal government took another small step in the battle

The growing antibiotic crisis: Much talk, little action

There are two items in today s news that address the 800 pou

Europe is ahead of the US in the antibiotics game, says Dr. Shlaes

We have often

Are hepatitis C drugs too expensive?

As we discussed

Subscribe to Dr. David Shlaes